Steven Pearson, ICER president (Jeff Rumans)

ICER pan­el says two ALS drug can­di­dates have 'low' long-term val­ue

ALS is well-known as one of the most dif­fi­cult drug tar­gets, and the US cost-ef­fec­tive­ness watch­dog ICER isn’t quite inch­ing clos­er to en­dors­ing the two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.